trending Market Intelligence /marketintelligence/en/news-insights/trending/tl9XGCrCtlRUxHf3kjDCbA2 content esgSubNav
In This List

JobLocationMap Q1 loss narrows YOY

Blog

Global smart TV forecast return to growth in 2022, sustained through 2026

Case Study

Broad Environmental Data Guides an Insurer’s Journey to Net Zero

Blog

Broadcast deal market recap, Q2'22

Blog

Japan M&A By the Numbers: Q1 2022


JobLocationMap Q1 loss narrows YOY

Bioscience Neutraceuticals Inc. said its first-quarter normalized net income was a loss of $2,180, compared with a loss of $2,320 in the year-earlier period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

Reported net income totaled a loss of $3,500, or a loss of 0 cents per share, compared to a loss of $3,710, or a loss of 0 cents per share, in the year-earlier period.